Artificial intelligence does not add a pillar to corporate governance. It tests each of the five the board already holds, and the minutes are the evidence of how the board responded.

A board's scarcest asset is its attention. Avancer's heat map rates twelve board duties by AI impact for health systems, medical device and diagnostics companies, pharmaceutical and biotechnology companies, and health plans, adjusts two duties for public companies, and shows how the ratings set the agenda.

When one committee owns artificial intelligence, the rest of the board stops asking about it. A federated model, written into the charters and coordinated by the chair, closes the gaps.

Most AI failures begin when a promising experiment is mistaken for a scalable product. The six gates of the Avancer AI Adoption at Scale Framework let the board see the difference.

If the return on an AI investment is easy to measure, the investment may not be ambitious enough. Boards need measures that fit the asset.

A sepsis model used in hundreds of hospitals performed far worse on one health system's patients than its developer reported. The lesson for boards lies in what happens when a model meets data it was never built for.

For boards, the question is no longer whether to engage with AI, but how. Four principles draw the series together, and the minutes hold them in place.